skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Melan-A VLP Vaccine (Code C61495)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Melan-A VLP Vaccine

Definition: A vaccine consisting of the melanocyte differentiation antigen Melan A (also called MART-1) encapsulated in noninfectious virus-like particles (VLP) with potential immunostimulating and antineoplastic activities. Upon administration, Melan-A VLP vaccine may activate the immune system to exert a specific cytotoxic T lymphocyte (CTL) response against cancer cells expressing the Melan A antigen, resulting in tumor cell lysis. Melan A is an antigen that is upregulated in most melanomas. VLP stimulates the immune system and promotes the CTL response.

Label: Melan-A VLP Vaccine

NCI Thesaurus Code: C61495 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1831836  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Melan-A VLP Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 506112
PDQ Open Trial Search ID 506112 (check for NCI PDQ open clinical trial info)
UMLS CUI C1831836

Other Properties:
     Name Value (qualifiers indented underneath)
code C61495
Legacy_Concept_Name Melan-A_VLP_Vaccine
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom